|
Inhibition of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa) Improves Efficacy of Tissue Plasminogen Activator (tPA) for Primary Lysis of Acute Pulmonary Thromboemboli (PE) in Rabbits
Petr Klement, Henderson Research Centre, Hamilton, Canada
|
|
The Antifibrinolytic Effect of Heparin - Exacerbation by Carboxypeptidases
John B Walker, Henderson Research Centre / McMaster University, Canada
|
|
A Study of the Role of Plasminogen, TAFIa, and High Molecular Weight Fibrin Degradation Products on the Rate of tPA Inhibition by PAI-1
Mr Mark M Schneider, Queen's University, Canada
|
|
Decreased Activity of Thrombin Activatable Fibrinolytic Inhibitor in Anticoagulated States: A Possible Explanation for the Observed Profibrinolytic Actions
Michelle R Florian-Kujawski, Loyola University Medical Center, United States
|
|
Migration of the Activation Peptide of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) during SDS-polyacrylamide Gel Electrophoresis
Ana HC Guimarães, Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
|
|
Development of an Elisa Exclusively Reacting with the Released Activation Peptide from TAFI (proCPU)
Erik PJ Ceresa, KULeuven, Belgium
|